In this context, recent data of treatment of DLBCL patients with tafasitamab (anti-CD19) and lenalidomide demonstrated an enhanced NK-cell–mediated antibody ADCC by tafasitamab in vitro (32–34). Here, CD19 is linked to diffuse large B-cell lymphoma.